Splitting Bluebird Bio into two publicly traded companies — one focused on cell therapies for cancer, the other on gene therapy for inherited diseases — is the best fix for the biotech’s recent struggles, CEO Nick Leschly told investors on Monday.
“Two birds are better than one,” said Leschly, speaking on a conference call in which he explained that dividing Bluebird into two companies “creates flexibility for each business,” “sharpens their focus,” and allows for “operational simplicity.”
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
